Zelluna ASA raises NOK 58m ahead of first TCR-NK clinical data
Zelluna ASA has completed a two-part equity raise totalling approximately NOK 58.2 million, comprising a NOK 55 million private placement and a NOK 3.2 million retail offering facilitated through Nordnet Bank AB. New shares were issued at NOK 18.50 per share, with 3,143,958 shares allocated in aggregate. The Euronext Oslo Børs-listed company said proceeds are intended to strengthen its financial position as it approaches initial clinical data from its lead programme and to preserve flexibility for future strategic activity.
The lead candidate underpinning the raise is ZI-MA4-1, which Zelluna describes as the first MAGE-A4-targeting off-the-shelf TCR-NK cell therapy to enter clinical development. MAGE-A4 is a cancer-testis antigen expressed across a range of solid tumour types, including synovial sarcoma, ovarian and bladder cancers, making it an attractive but historically challenging immunotherapy target. Initial clinical data from the ZI-MA4-1 programme are expected to emerge from mid-2026, a window the company confirmed remains on track.
Platform and scientific context
Zelluna's TCR-NK platform attempts to combine two distinct mechanisms: the innate cytotoxic activity of natural killer cells with the antigen-specific targeting precision of T cell receptors. The rationale is to address a persistent limitation of existing CAR-T approaches in solid tumours, where immunosuppressive microenvironments and poor T cell persistence have hampered efficacy. By engineering NK cells to carry tumour-specific TCRs, the company is pursuing an allogeneic, or off-the-shelf, product that avoids the manufacturing complexity and patient-level variability associated with autologous therapies.
Chief executive Namir Hassan said the financing "strengthens Zelluna's position as we advance ZI-MA4-1, continue to expand the potential of our TCR-NK platform and approach anticipated initial clinical data." The company has appointed ABG Sundal Collier ASA as manager and bookrunner for the private placement; Advokatfirmaet BAHR AS is acting as legal adviser.
Competitive landscape
The broader field of allogeneic cell therapy for solid tumours is congested and has seen a number of clinical setbacks in recent years, particularly among CAR-NK and CAR-T programmes targeting haematological malignancies that have struggled to demonstrate durable benefit in solid indications. Zelluna's TCR-based approach is differentiated from antibody-derived constructs and positions the company in a relatively narrow but scientifically credible subsegment. Several academic and venture-backed groups are pursuing TCR-engineered NK strategies, though few have reached the clinical stage with an off-the-shelf format and a defined solid tumour antigen target.
For investors, the key near-term catalyst is the initial ZI-MA4-1 clinical read. Early safety and tolerability data will be scrutinised closely, given the chequered history of solid tumour cell therapies, and any signal of antigen-directed activity in patients will be significant for the platform's credibility. With the raise extending the company's financial runway, Zelluna has reduced its immediate dilution risk and bought time to let its clinical story develop before returning to the market.